Activity by Joe Dangor
ROCHESTER, Minn. â€” The genetic makeup of colon cancer tumors and survival rates for patients with the disease differ by race, according to a study from researchers at the Mayo Clinic Cancer Center, published in the October 2015 issue of theÂ Journal of the National Cancer Institute.
â€śThese findings put the issue of race more prominently on the radar of investigators that cancer biology may contribute to race-based disparities,â€ť says the studyâ€™s co-lead author, Harry Yoon, M.D., an oncologist at Mayo Clinic. â€śWhile it is too early to change the way we treat these patients, our results indicate that future studies are needed to examine potential biological drivers of these differences more closely.â€ť
According to the American Cancer Society, colon cancer is the third most common cancer in both men and women with more than 93,000 cases estimated to be diagnosed in 2015. Researchers have long known that blacks develop colon cancer at an earlier age and blacks with colon cancer are at higher risk of dying than whites. However, it has been difficult to identify why the differences in survival exist.
Journalists: Sound bites with Dr. Yoon are available in the downloads.
The ups and downs of incorporating a new treatment to try to prevent chemotherapy-associated neuropathy
ROCHESTER, Minn. â€” In this age of the 24-hour news cycle, instant access to all information everywhere, PubMed, LinkedIn, Facebook, Twitter and hundreds of other ways to glean and share knowledge beyond the traditional stack of printed journals delivered to their door, physicians continue to struggle to arm themselves with the most effective therapies.
Fast access to information may result in practice change; however, subsequent data may disprove effectiveness and require even more practice change. The cycle may continue over several years and several studies, with the potential for missed information growing with each practice-change decision.
In a study released today in the Journal of the National Comprehensive Cancer Network, Mayo Clinic researchers, looking at one drug used for one condition, show how, even in a fairly narrow field with limited general consumer involvement, the quick penetration of information resulted in several practice shifts and reversals across the nation that stretched over a decade. The researchers looked at the timeline and impacts of various events on the use of calcium magnesium (CaMg) for oxaliplatin-induced neuropathy.
ROCHESTER, Minn. â€“ Mayo Clinic researchers have identified a protein marker whose frequency may predict patient response to PD-1 blockade immunotherapy for melanoma. An abstract of their findings was presented today at the American Association for Cancer Research International Cancer Immunotherapy Conference in New York City.
â€śThe discovery of biomarkers of sensitivity are vital not only for informing clinical decisions, but also to help identify which patients with melanoma, and possibly other malignancies, who are most likely to benefit from PD-1 blockade," says Roxana Dronca, M.D., a hematologist at Mayo Clinic and lead author of the abstract. â€śThis will allow us to expose fewer patients to inadequate treatments, and their associated toxicities and costs.â€ť
Journalists: Â Sound bites with Dr. Dronca are available in the downloads.
ROCHESTER, Minn. â€” Low-risk cancers that do not have any symptoms and presumably will not cause problems in the future are responsible for the rapid increase in the number of new cases of thyroid cancer diagnosed over the past decade, according to a Mayo Clinic study published in the journal Thyroid. According to the study authors, nearly one-third of these recent cases were diagnosed when clinicians used high-tech imaging even when no symptoms of thyroid disease were present.
â€śWe are spotting more cancers, but they are cancers that are not likely to cause harm,â€ť says the study's lead author, Juan Brito Campana, M.B.B.S., an assistant professor of medicine at Mayo Clinic. â€śTheir treatment, however, is likely to cause harm, as most thyroid cancers are treated by surgically removing all or part of the thyroid gland. This is a risky procedure that can damage a patientâ€™s vocal cords or leave them with lifelong calcium deficiencies.â€ť
MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005,Â firstname.lastname@example.org [...]
ROCHESTER, Minn. â€” Imetelstat, a novel drug that targets telomerase, has demonstrated potential value in treating patients with myelofibrosis, according to the results of a study published today in the New England Journal of Medicine.
"We observed that Imetelstat was active and induced morphologic and molecular remissions in some patients with myelofibrosis," says Ayalew Tefferi, M.D., a hematologist at Mayo Clinic and lead author of the study. "We also observed that Imtelstat demonstrated selective anti-clonal activity, inhibiting the growth of cancer cells, which we had not previously documented with other drugs."
MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005,Â email@example.com
Journalists: Sounds bites with Dr. Tefferi are available in the downloads.
ROCHESTER Minn. â€” A team of Mayo Clinic Cancer Center scientists has been awarded a Specialized Program of Research Excellence (SPORE) grant in multiple myeloma from the National Cancer Institute. The Mayo Clinic Cancer Center is one of only three cancer centers to receive a SPORE grant for multiple myeloma cancer research.
â€śWith project leaders from Mayo campuses in Arizona, Rochester and Florida, our SPORE team will study the genetic basis for myeloma, develop novel viral and immunologic therapies, and optimize the use of existing therapies with a goal of controlling and eventually curing this deadly disease,â€ť says Leif Bergsagel, M.D., lead investigator. â€śStarting from the pioneering work of Robert Kyle, M.D., over the last half-century, the myeloma group at Mayo Clinic is one of the strongest in the world.â€ť
Journalists: Sound bites with Dr. Bergsagel are available in the downloads.
PHOENIX -- A multicenter study involving Mayo Clinic researchers has found that the National Cancer Institute's Patient Reported Outcomes version ofÂ the Common Terminology Criteria for Adverse Events (PRO-CTCAE), was accurate, reliable and responsive, compared to other, established patient-reported and clinical measures. The study is published today in the journal JAMA Oncology.
â€śIn most cancer clinical trials, information on side effects is collected by providers who have limited time with their patients and current patient questionnaires are limited in scope and depth," says the study's lead author Amylou Dueck, Ph.D., a biostatistician on Mayo Clinicâ€™s Arizona campus. "PRO-CTCAE is a library of items for patients to directly report on the level of each of their symptoms, to enhance the reporting of side effects in cancer clinical trials which is normally based on information from providers. The study itself is unprecedented as more than 100 distinct questions about symptomatic adverse events were validated simultaneously."
Researchers recruited more than 1,000 patients from nine clinical practices across the U.S., including seven cancer centers. These patients reflected the geographic, ethnic, racial and economic diversity in cancer clinical trials. Patients in the study also had a wide range of cancer types.
EDEN PRAIRIE and ROCHESTER, Minn., Aug. 5, 2015 â€” Optum and Mayo Clinic announced that health plans and employers participating in Optumâ€™s leading Centers of Excellence (COE) program now have access to high-quality, cost-effective care from Mayo Clinic care providers who are experts in treating complex and rare conditions.
Optumâ€™s Centers of Excellence provide best-in-class capabilities with proven clinical quality and predictable consumer outcomes. The Center of Excellence designation includes condition-specific, high-performing programs with specialized clinical expertise and care management to support consumer engagement.
Mayo Clinic has participated in Optumâ€™s Transplant COE program for the last 11 years. With this expanded relationship, Mayo Clinic is now also a participant in Optumâ€™s Centers of Excellence for Cancer, Bariatric Surgery and Heart Failure for Mayo Clinic locations in Arizona, Florida and Rochester, Minn.
Mayo Clinicâ€™s Rochester location is also participating in Optumâ€™s COEs for Congenital Heart Disease and Infertility services.
â€śThis expanded relationship with Mayo Clinic provides patients in participating health plans from around the country with greater access to clinically superior, cost-effective health care,â€ť said Mike Weissel, CEO of Optum Consumer Solutions.